Alibaba Cloud Launches Malaysia City Brain to Enhance City Management
Alibaba Cloud, the cloud computing arm of Alibaba Group, today announced the launch of its Malaysia City Brain initiative in collaboration with the Malaysia Digital Economy Corporation (MDEC), the country’s digital economy development agency, and Dewan Bandaraya Kuala Lumpur (DBKL), the city council in the capital, at a ceremony in Kuala Lumpur.
The Malaysia City Brain initiative is a significant milestone because it’s the first time for the City Brain solution to be adopted overseas. It is developed on Alibaba Cloud’s robust cloud computing infrastructure and will support Malaysia’s digital transformation with cloud technology and artificial intelligence.
Powered by Alibaba Cloud’s large-scale computing engine Apsara, Malaysia City Brain offers a comprehensive suite of acquisition, integration, and analysis of big and heterogeneous data generated by a diversity of sources in urban spaces through video and image recognition, data mining and machine learning technology. The power and functionality of the City Brain will enable Malaysian urban planners and city officials to upgrade their city governance and decision-making to turn the city into an intelligent one.
In the first phase of the program, the capital Kuala Lumpur will roll out the Malaysia City Brain for use in traffic management to improve mobility in the city. With its massive cloud computing and data processing capabilities, the City Brain can optimise the flow of vehicles and traffic signals by calculating the time to reach intersections. It will also be able to generate structured summaries of data, such as traffic volume and speed in particular lanes, which can be used to facilitate other tasks including incident detection.
In addition, City Brain can connect with various urban management systems including emergency dispatch, ambulance call, traffic command, and traffic light control. By integrating and analysing real-time data generated from these systems, City Brain can optimize urban traffic flow such as by identifying the quickest route for emergency vehicles to arrive at the scene within the shortest time frame.
As the City Brain’s functionality expands, enterprises, start-ups, entrepreneurs, universities, and research institutions will in the future also have the opportunity to access and leverage its artificial intelligence tools to drive a wide range of innovation.
On the crucial integration of artificial intelligence, Simon Hu, Senior Vice President of Alibaba Group and President of Alibaba Cloud, commented: “Cloud computing, data technology and AI has become fundamental tools for all companies and organizations to operate effectively. Building on this partnership, we are happy to see Malaysia become the first country outside of China to adopt the City Brain. Through the program, we aim to empower all Malaysian stakeholders in both the public and private sectors with the tools to enhance efficiency, advance innovation and succeed in the digital age. For Alibaba Cloud, this is the true meaning of inclusive technology.”
Dato’ Yasmin Mahmood, Chief Executive Officer of MDEC, said: “The collaboration with Alibaba Group is another leap towards digitizing Malaysia where knowledge-sharing and the crossover of best practices transpire. As we set our sights on the future, we are excited about the prospects this partnership will bring to our community, and benefiting Malaysians with the tangible results of digital solutions.”
Malaysia Tianchi Big Data Program
At the same event, Alibaba Cloud also announced the Malaysia Tianchi Big Data Program, a big data crowd intelligence platform that brings together global data experts to collaborate and compete in developing solutions for real world problems. Backed by MDEC, the initiative aims to incubate 500 data professionals and 300 startups in Malaysia within two years by facilitating the use of world class data intelligence technology through Alibaba Cloud’s cloud computing infrastructure and artificial intelligence capabilities.
The Malaysia Tianchi Big Data Program will be integrated into Alibaba Cloud’s Tianchi global community which already boasts over 120,000 developers and 2,700 academic institutes and businesses from 77 countries and regions. By participating in these big data competitions, Malaysian experts will compete with, and learn from, counterparts across the globe to develop best-in-class data technology, keeping Malaysia at the forefront of the global digital economy.
Malaysia City Brain and Tianchi are just the latest step in a successful partnership between Alibaba and MDEC. In March 2017, Alibaba Group announced the setup of the first overseas e-hub under Electronic World Trade Platform (eWTP) in Malaysia. Alibaba Cloud has made significant progress on this endeavour since. In October 2017, Alibaba Cloud opened a data center in Malaysia, which became the first global public cloud platform in the country. The data center provides Malaysian enterprises with a local choice to build their businesses on a powerful, reliable and secure cloud platform.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com), the cloud computing arm of Alibaba Group, is among the world’s top three IaaS providers according to Gartner, and the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and government organisations. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme